7 March Washington
9:40 Development of a Novel Neuroprotective Molecule for Mild TBI/Concussion
In this presentation Mr. Glass will discuss the product development pathway for a neuroprotectant molecule from discovery through early-stage clinical trials. The presentation will cover discovery, pharmacology, oral formulation development, regulatory strategy and clinical trial considerations for NNZ-2566, a synthetic analog of the naturally occurring neuropeptide, IGF-1(1-3).
Larry Glass, Chief Executive Officer, Neuren Pharmaceuticals
conference starts today, page-5
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.62 |
Change
-0.240(1.15%) |
Mkt cap ! $2.635B | |||
| Open | High | Low | Value | Volume |
| $20.45 | $20.62 | $20.26 | $4.698M | 229.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 221 | $20.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.62 | 1553 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |